Who are we
Deep Science Ventures is a venture builder focused on rapidly creating enormous impact via the hard sciences.
Why we started DSV
Deep Science Ventures evolved out of 5 years of working with academics to shape technology to fit the market at Imperial Innovations, the leading research commercialisation investor across the UKs 4 top universities.

During the last 5 years we have worked with scientists to build companies, from scratch, across domains from biochemistry to nano-tech. Many of those ventures have already gone on to considerable exits to the likes of Google (Hark, now part of DeepMind Health) and Facebook (Surreal Vision, now part of the Oculus team), whilst over 75% are continuing to grow. It's been an incredible journey, but we think there's a much bigger challenge.

Given how many people want to drive enormously ambitious change, the necessary collisions between deep scientific and commercial expertise are surprisingly rare. We left Imperial last summer to change this and we're already starting to see some incredible exciting ventures emerge.
Our Team
Mario Branciforti
AI, semiconductors, heavy engineering
Mario is a Principal on the investment team at Touchstone Innovations where he focuses on SaaS, machine intelligence and cybersecurity, working with import.io, Telectic and Garrison Technology among others. Previously lead strategy at NXP Semiconductors through to IPO in 2010, and Symantec.cloud, formerly MessageLabs, acquired in 2008.
Inmaculada Martinez
Data & behaviour

Originally a pioneer in WAP technology she has founded and sold several businesses all with a common theme of data and behavioral modeling. Inma was a partner at Opus Corporate Finance, is a Catalyst Member of UKTI and advises on deriving value from data in across huge number of industries for companies including IBM, HP, P&G, Unilever, IDEO, Blackrock, Sony and many others.
Jason C. Foster
Healthcare & pharma

Senior healthcare advisor specialising in marketing and operations. Previously at Reckitt Benckiser leading the growth of the global pharma business to $1.1B in revenue and a £2B LSE listing.
Jonathan Crouch
Agritech & bioeconomy

Over 20 years experience of technology development and bioscience venture creation globally, including establishing an incubator, biotech platforms, and PPPs. Most recently he built out a $60m facility at CDC for supporting early stage investments across sectors in Africa and South Asia. Jonathan originally comes from a research background in genomics, transgenics, computational biology and breeding.
Dr Mark Hammond
Director
Background in Neuropharmacology and AI before moving on to spend 8 years working with academics to build early stage high-tech companies (from computing to chemistry including 4 big-name exits) both at a clean-tech focused investment boutique and Imperial College's commercialisation arm Imperial Innovations.

mark@dsv.io
Dominic Falcão
Director
Previously 3 years building Imperial College's start-up community from zero to 3000 scientists, founded a social enterprise consultancy and worked in marketing at several digital start-ups.

dom@dsv.io
Santa Astratova
Ecosystem Development Manager
Previously business mentor at Australia's leading business incubator, Cicada Innovations. Worked with over 70 advanced tech start-ups in areas of customer development, capital raising and business growth. Managed a med-tech commercialisation training program helping 9 companies raise over $13M in private and public investment over two years.

santa@dsv.io
Dr Francis Lister
Special Projects Lead
Joining us from the Alpha cohort, Francis has a PhD in organic chemistry in which he created a synthetic version of the GPCR receptor, work that has since been published in Nature Chemistry. He also has experience working in several advanced tech start-ups. Francis runs our project co-creation activities and is dedicated to ensuring teams scale rapidly by ensuring availability of the required facilities and expertise.

francis@dsv.io
Made on
Tilda